NYSE:RCUS Arcus Biosciences (RCUS) Stock Forecast, Price & News $18.75 -0.45 (-2.34%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$18.51▼$19.3550-Day Range$17.62▼$23.0452-Week Range$15.70▼$36.13Volume571,436 shsAverage Volume999,003 shsMarket Capitalization$1.40 billionP/E RatioN/ADividend YieldN/APrice Target$44.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcus Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside134.7% Upside$44.00 Price TargetShort InterestHealthy13.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 4 Articles This WeekInsider TradingAcquiring Shares$19.45 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($4.33) to ($3.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.61 out of 5 starsMedical Sector124th out of 976 stocksBiotechnology Industry3rd out of 21 stocks 4.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.00, Arcus Biosciences has a forecasted upside of 134.7% from its current price of $18.75.Amount of Analyst CoverageArcus Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.62% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 11.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 1.7 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcus Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have bought 1,331.19% more of their company's stock than they have sold. Specifically, they have bought $19,452,600.00 in company stock and sold $1,359,194.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.67% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($4.33) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcus Biosciences (NYSE:RCUS) StockArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More RCUS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCUS Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comPrecision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial DiseasesSeptember 24, 2023 | fool.comArcus Biosciences (NYSE: RCUS)September 28, 2023 | Altimetry (Ad)Advisor to FBI: Sell META nowStocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.September 19, 2023 | markets.businessinsider.comTruist Financial Remains a Buy on Arcus Biosciences (RCUS)September 7, 2023 | msn.comTruist Securities Reiterates Arcus Biosciences (RCUS) Buy RecommendationSeptember 5, 2023 | finance.yahoo.comArcus Biosciences (RCUS): A Modestly Undervalued Gem?September 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Neurocrine (NBIX) and Arcus Biosciences (RCUS)August 24, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Arcus BiosciencesSeptember 28, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 24, 2023 | msn.comMizuho Reiterates Arcus Biosciences (RCUS) Buy RecommendationAugust 23, 2023 | msn.comGilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial dataAugust 23, 2023 | finance.yahoo.comArcus Biosciences to Participate in Multiple Upcoming Investor ConferencesAugust 23, 2023 | finance.yahoo.comArcus Biosciences: A Modestly Undervalued Opportunity?August 23, 2023 | markets.businessinsider.comArcus Biosciences (RCUS) Receives a Buy from Mizuho SecuritiesAugust 17, 2023 | msn.comHC Wainwright & Co. Maintains Precision Biosciences (DTIL) Buy RecommendationAugust 17, 2023 | msn.comWhat Is Precision BioSciences CAR T Pipeline Value? Analyst Lowers Price Target To Justify ValuationAugust 7, 2023 | markets.businessinsider.comArcus Biosciences, Inc Q2 Loss increases, but beats estimatesAugust 7, 2023 | msn.comArcus Biosciences GAAP EPS of -$1.04, revenue of $29MAugust 7, 2023 | finance.yahoo.comArcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline UpdateAugust 4, 2023 | finance.yahoo.comPrecision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 4, 2023 | benzinga.comPreview: Arcus Biosciences's EarningsJuly 27, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Arcus Biosciences (RCUS)July 12, 2023 | benzinga.comCantor Fitzgerald Reinstates Overweight on Arcus Biosciences, Maintains $46 Price TargetJuly 12, 2023 | msn.comCantor Fitzgerald Reiterates Arcus Biosciences (RCUS) Overweight RecommendationJuly 9, 2023 | seekingalpha.comAcumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023July 6, 2023 | benzinga.comArcus Biosciences 13D Filing Shows Gilead Sciences, Inc. Increased Stake In Co To 35%June 15, 2023 | msn.comArcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But FrustratesSee More Headlines Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Company Calendar Last Earnings8/07/2023Today9/28/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.00 High Stock Price Forecast$70.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+134.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-267,000,000.00 Net Margins-235.99% Pretax Margin-233.59% Return on Equity-45.51% Return on Assets-22.02% Debt Debt-to-Equity RatioN/A Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$112 million Price / Sales12.47 Cash FlowN/A Price / Cash FlowN/A Book Value$9.07 per share Price / Book2.07Miscellaneous Outstanding Shares74,500,000Free Float64,222,000Market Cap$1.40 billion OptionableOptionable Beta0.82 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Terry J. Rosen Ph.D. (Age 63)Co-Founder, Chairman & CEO Comp: $756.11kDr. Juan Carlos Jaen Ph.D. (Age 65)Co-Founder, Pres & Director Comp: $931.14kMr. Robert C. Goeltz II (Age 50)Principal Financial Officer & CFO Comp: $745.29kMs. Jennifer A. Jarrett M.B.A. (Age 52)COO & Director Comp: $925.29kDr. Dimitry S.A. Nuyten M.D. (Age 47)Ph.D., Chief Medical Officer Comp: $700.34kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Alexander Azoy (Age 47)VP of Fin. & Principal Accounting Officer Dr. Stephen Young Ph.D. (Age 54)Sr. VP of Technology & Quantitative Biology Dr. Jonathan Yingling Ph.D. (Age 54)Chief Scientific Officer Ms. Katherine BockVP of Investor Relations & Corp. StrategyMore ExecutivesKey CompetitorsTaro Pharmaceutical IndustriesNYSE:TAROZentalis PharmaceuticalsNASDAQ:ZNTLIronwood PharmaceuticalsNASDAQ:IRWDAbCellera BiologicsNASDAQ:ABCLAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInsiders & InstitutionsJennifer JarrettSold 21,369 sharesTotal: $427,166.31 ($19.99/share)Barclays PLCBought 3,642 shares on 9/21/2023Ownership: 0.223%Virginia Retirement Systems ET ALBought 40,200 shares on 8/22/2023Ownership: 0.054%California State Teachers Retirement SystemSold 1,172 shares on 8/21/2023Ownership: 0.075%Teachers Retirement System of The State of KentuckyBought 912 shares on 8/21/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions RCUS Stock - Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCUS shares. View RCUS analyst ratings or view top-rated stocks. What is Arcus Biosciences' stock price forecast for 2023? 9 Wall Street analysts have issued 1 year target prices for Arcus Biosciences' stock. Their RCUS share price forecasts range from $23.00 to $70.00. On average, they expect the company's share price to reach $44.00 in the next year. This suggests a possible upside of 134.7% from the stock's current price. View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts. How have RCUS shares performed in 2023? Arcus Biosciences' stock was trading at $20.68 on January 1st, 2023. Since then, RCUS stock has decreased by 9.3% and is now trading at $18.75. View the best growth stocks for 2023 here. When is Arcus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our RCUS earnings forecast. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) announced its earnings results on Monday, August, 7th. The company reported ($1.04) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.06. The business earned $29 million during the quarter, compared to analyst estimates of $31.81 million. Arcus Biosciences had a negative net margin of 235.99% and a negative trailing twelve-month return on equity of 45.51%. Arcus Biosciences's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.93) earnings per share. What ETFs hold Arcus Biosciences' stock? ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and Invesco S&P SmallCap Health Care ETF (PSCH).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. What is Arcus Biosciences' stock symbol? Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS." Who are Arcus Biosciences' major shareholders? Arcus Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (12.71%), State Street Corp (5.83%), Boxer Capital LLC (2.15%), Dimensional Fund Advisors LP (1.56%), Alliancebernstein L.P. (1.40%) and Geode Capital Management LLC (1.38%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcus Biosciences' stock price today? One share of RCUS stock can currently be purchased for approximately $18.75. How much money does Arcus Biosciences make? Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.40 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis. How many employees does Arcus Biosciences have? The company employs 500 workers across the globe. How can I contact Arcus Biosciences? Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com. This page (NYSE:RCUS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.